EA200100828A1 - 16-гидроксиэстратриены в качестве эстрогенов избирательного действия - Google Patents

16-гидроксиэстратриены в качестве эстрогенов избирательного действия

Info

Publication number
EA200100828A1
EA200100828A1 EA200100828A EA200100828A EA200100828A1 EA 200100828 A1 EA200100828 A1 EA 200100828A1 EA 200100828 A EA200100828 A EA 200100828A EA 200100828 A EA200100828 A EA 200100828A EA 200100828 A1 EA200100828 A1 EA 200100828A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new compounds
estrogen receptor
preparations
rat
describes
Prior art date
Application number
EA200100828A
Other languages
English (en)
Inventor
Герман Кюнцер
Рудольф Кнауте
Моника Лессль
Карл-Генрих Фрицемайер
Криста Хегеле-Хартунг
Ульф Бёмер
Герд Мюллер
Дирк Коземунд
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200100828A1 publication Critical patent/EA200100828A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings

Abstract

В заявке описываются новые соединения в качестве фармацевтически активных веществ, характеризующиеся более высокой степенью аффиности in vitro на препаратах эстрогенного рецептора простаты крысы в сравнении с этим показателем на препаратах эстрогенного рецептора матки крысы и предпочтительно проявляющих in vivo преимущественную эффективность по отношению к костной ткани в сравнении с воздействием на матку и/или оказывающих четко выраженное воздействие на стимуляцию экспрессии 5НТ2а-рецептора и переносчика. В заявке описываются также получение предлагаемых соединений, их применение в терапии и фармацевтические лекарственные формы, содержащие эти новые соединения. Новые соединения представляют собой 16α- и 16β-гидроксиэстра-1,3,5(10)-эстратриены, которые в стероидном скелете могут нести другие заместители, а в кольцах В, С и D могут иметь одну или несколько дополнительных двойных связей.Отчет о международном поиске был опубликован 2001.08.02.
EA200100828A 1999-02-09 2000-02-09 16-гидроксиэстратриены в качестве эстрогенов избирательного действия EA200100828A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19906159A DE19906159A1 (de) 1999-02-09 1999-02-09 16-Hydroxyestratriene als selektiv wirksame Estrogene
PCT/EP2000/001073 WO2000047603A2 (de) 1999-02-09 2000-02-09 16-hydroxyestratriene als selektiv wirksame estrogene

Publications (1)

Publication Number Publication Date
EA200100828A1 true EA200100828A1 (ru) 2002-04-25

Family

ID=7897485

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100828A EA200100828A1 (ru) 1999-02-09 2000-02-09 16-гидроксиэстратриены в качестве эстрогенов избирательного действия

Country Status (30)

Country Link
EP (2) EP1144431B1 (ru)
JP (1) JP2002536455A (ru)
KR (1) KR20010101822A (ru)
CN (1) CN1346364A (ru)
AR (1) AR034392A1 (ru)
AT (1) ATE313553T1 (ru)
AU (1) AU2909500A (ru)
BG (1) BG105804A (ru)
BR (1) BR0008076A (ru)
CA (1) CA2359660A1 (ru)
CO (1) CO5150223A1 (ru)
CZ (1) CZ20012843A3 (ru)
DE (2) DE19906159A1 (ru)
DK (1) DK1144431T3 (ru)
EA (1) EA200100828A1 (ru)
EE (1) EE200100412A (ru)
ES (1) ES2255983T3 (ru)
HK (1) HK1046145A1 (ru)
HU (1) HUP0200055A3 (ru)
IL (1) IL144455A0 (ru)
MX (1) MXPA01008065A (ru)
NO (1) NO20013860L (ru)
NZ (1) NZ513409A (ru)
PE (1) PE20001461A1 (ru)
PL (1) PL350360A1 (ru)
PT (1) PT1144431E (ru)
SK (1) SK11302001A3 (ru)
WO (1) WO2000047603A2 (ru)
YU (1) YU57201A (ru)
ZA (1) ZA200107388B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
DE10048634A1 (de) * 2000-09-27 2002-04-18 Jenapharm Gmbh 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring
DE10151365A1 (de) 2001-10-17 2003-04-30 Schering Ag 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten
DK1365768T3 (da) * 2001-02-27 2008-08-18 Bayer Schering Pharma Ag Anvendelse af ER-beta-selektive antagonister som contraception.
DE10151114A1 (de) * 2001-10-15 2003-04-17 Schering Ag 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
SE536263C2 (sv) * 2011-12-21 2013-07-23 Airqone Building Scandinavia Ab Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft
PL3500265T3 (pl) * 2016-08-22 2024-03-11 Or-Genix Therapeutics, Inc. Selektywne ligandy receptora estrogenowego beta
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
JP2021535183A (ja) * 2018-09-07 2021-12-16 トラスティーズ・オヴ・ダートマス・カレッジ Ｃ１９骨格およびステロイドならびにそれらの使用および製造方法
CN115154474A (zh) * 2021-04-01 2022-10-11 中国人民解放军总医院 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079408A (en) * 1963-02-26 Ig-bisoxygenated iy-haloestra-
US3103524A (en) * 1963-09-10 Ratetraene-
GB823955A (en) * 1955-09-01 1959-11-18 Nepera Chemical Co Inc Improvements in steroid compounds and method for manufacture of same
GB804789A (en) * 1956-02-06 1958-11-26 Searle & Co 16-alkylestratriene-3,16,17-triols and derivatives thereof
US2779773A (en) * 1956-05-23 1957-01-29 Nepera Chemical Co Inc Steroid 3, 16alpha-diols and process
US3166473A (en) * 1962-04-12 1965-01-19 Mochida Pharm Co Ltd New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol
NL124324C (ru) * 1964-01-24
FR4339M (ru) * 1965-03-29 1966-08-08
FR5099M (ru) * 1966-01-12 1967-05-22
US3449383A (en) * 1967-02-16 1969-06-10 Searle & Co 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof
US3470159A (en) * 1967-07-13 1969-09-30 American Home Prod Estra-1,3,5(10),7-tetraenes and process of preparation
CH538460A (de) * 1969-02-27 1973-06-30 Ciba Geigy Ag Verfahren zur Herstellung eines neuen hochwirksamen Östratriols
FR2034569B1 (ru) * 1969-02-27 1973-07-13 Ciba Geigy Ag
GB1235642A (en) * 1969-02-27 1971-06-16 Ciba Geigy A new oestratriol and a process for its manufacture
CH537915A (de) * 1969-02-27 1973-06-15 Ciba Geigy Ag Verfahren zur Herstellung eines neuen Östratriols
US3600705A (en) * 1969-02-27 1971-08-17 Gen Electric Highly efficient subcritically doped electron-transfer effect devices
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
IL38806A0 (en) * 1971-03-05 1972-04-27 Ciba Geigy Ag Pharmaceutical compositions comprising estrogens and anthracene derivatives
US3766224A (en) * 1971-06-03 1973-10-16 Sandoz Ag 15-methyl-substituted steroids
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
JPS5265259A (en) * 1975-11-27 1977-05-30 Takeda Chem Ind Ltd Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
DD145919B1 (de) * 1978-06-28 1982-06-30 Kurt Ponsold Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe
SE8305596D0 (sv) * 1983-10-12 1983-10-12 Leo Ab A selective acylation method
DE3510555A1 (de) * 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen Estriolester
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
HU208150B (en) * 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
SU1761760A1 (ru) * 1990-07-02 1992-09-15 Всесоюзный Эндокринологический Научный Центр Амн Ссср Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
DE4322186A1 (de) * 1993-07-03 1995-01-12 Jenapharm Gmbh Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie

Also Published As

Publication number Publication date
NZ513409A (en) 2004-02-27
AU2909500A (en) 2000-08-29
ES2255983T3 (es) 2006-07-16
CZ20012843A3 (cs) 2002-01-16
WO2000047603A9 (de) 2001-09-07
ZA200107388B (en) 2005-01-25
KR20010101822A (ko) 2001-11-14
PL350360A1 (en) 2002-12-02
HUP0200055A2 (hu) 2002-05-29
EE200100412A (et) 2002-12-16
NO20013860D0 (no) 2001-08-08
PT1144431E (pt) 2006-05-31
HK1046145A1 (zh) 2002-12-27
YU57201A (sh) 2005-06-10
PE20001461A1 (es) 2000-12-18
CN1346364A (zh) 2002-04-24
WO2000047603A2 (de) 2000-08-17
JP2002536455A (ja) 2002-10-29
NO20013860L (no) 2001-10-08
DE19906159A1 (de) 2000-08-10
WO2000047603A3 (de) 2001-08-02
IL144455A0 (en) 2002-05-23
DK1144431T3 (da) 2006-05-08
HUP0200055A3 (en) 2002-10-28
EP1144431A2 (de) 2001-10-17
EP1144431A3 (de) 2002-06-12
SK11302001A3 (sk) 2002-01-07
ATE313553T1 (de) 2006-01-15
AR034392A1 (es) 2004-02-25
BR0008076A (pt) 2002-02-05
CO5150223A1 (es) 2002-04-29
EP1144431B1 (de) 2005-12-21
EP1580192A2 (de) 2005-09-28
CA2359660A1 (en) 2000-08-17
BG105804A (en) 2002-03-29
MXPA01008065A (es) 2002-04-24
DE50011908D1 (de) 2006-01-26

Similar Documents

Publication Publication Date Title
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
ATE302790T1 (de) 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate
EA200201000A1 (ru) Гормон-заместительная терапия
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
EA200301022A1 (ru) Гормональная заместительная терапия
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
TR199801915T2 (xx) Benzotiofenler, bunlar� ihtiva eden form�lasyonlar ve y�ntemler.
DK1226155T3 (da) 18-nor-steroider som selektivt virksomme östrogener
ZA90962B (en) Phenylhydrazones,the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
EA200500661A1 (ru) Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты)
WO2003104253A3 (de) 9-alpha-substituierte estratriene als selektiv wirksame estrogene
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
JPH0769883A (ja) アロマターゼ阻害剤
GB9808582D0 (en) Improvements in or relating to contrast agents
BR0113618A (pt) 17-metilenoesteróides, processos para a sua preparação e composições farmacêuticas contendo estes compostos
PL352029A1 (en) 14-beta-h-sterols, pharmaceutical compositions containing these sterols and use of these derivatives for obtaining drugs to regulate meioses
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
EA200100801A1 (ru) Применение половых гормонов при изготовлении фармацевтической композиции для назального введения, предназначенной для лечения нежелательного маточного кровотечения
ITCA20000007A1 (it) Fitoestrogeni da soli o in combinazione per uso contraccetivo e terape utico.